The clinical significance of the increased expression levels of BID gene in Larynx Cancer

Creative Commons License

Demokan S., Şen S., Doruk C., Esentürk Yayla K. G., Ulusan M.

o 7th INTERNATİONAL CONGRESS OF THE MOLECULAR BİOLOGY, İstanbul, Turkey, 27 - 29 September 2019, vol.5, no.43, pp.53

  • Publication Type: Conference Paper / Summary Text
  • Volume: 5
  • City: İstanbul
  • Country: Turkey
  • Page Numbers: pp.53
  • Gazi University Affiliated: Yes


Aim: Apoptosis is a programmed cell death, a physiological event that regulates the homeostasis of the organism by the destruction of unnecessary/damaged cells without an inflammatory response. The BID (BH3 Interacting Domain Death Agonist) protein, encoded by the BID gene, is a member of the BCL2 family that regulates apoptosis by activating the mitochondrial death pathway via Caspase 8, allowing cytochrome C to be released. In the literature, increased expression levels of BID gene have been observed in glioma, lymphoma, colon, prostate and cervical cancers; while in Hepatitis B Virus (HBV) infected hepatocellular carcinoma, its decreased expression levels have been reported. In our study (I.U.BAP-ONAP-42152), we aimed to investigate the differentially expressed levels of BID gene in Turkish larynx cancer patients and to reveal the clinical significance.

Methods: The expression status of BID was analyzed in tumor and matched-normal tissue samples of 50 larynx cancer patients using LightCycler 480 by the quantitative real-time polymerase chain reaction method. The results were compared with clinicopathological data.

Results: BID and the reference gene expression status were analyzed by calculating the threshold cycle numbers (Ct) as fold changes using the 2-ΔΔCt method. After evaluation of the expression levels, we selected the ratio of >=2 as the threshold for the differentially expressed BID. The increased expression levels of BID were observed in 46% (23/50) of tumor samples compared with matched normal tissue, whereas the expression levels were decreased in 28% (14/50) of patients. The statistical significanceswere observed between the increased expression levels of BIDwith recurrence (p=0.024) and anatomical region (p=0.018).

Conclusion: The increase in the expression level of the BID gene is thought to be associated with the development and recurrence of larynx cancer.

Keywords: Larynx cancer, expression, BID gene